About Perseo pharma

Perseo pharma is a start-up company with state-of-the-art labs located in Basel, Switzerland. It is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Muttenz (near Basel).

The technology was invented by Prof. Dr. Patrick Shahgaldian (FHNW), who acts as CSO of the company.

Who we are

Dr. Yves Dudal
CEO

A Bioprocess engineer by training (National Institute for Applied Sciences, INSA Toulouse, France), Yves received his PhD in chemical engineering from Polytechnique Montréal, Canada in 2000. He worked for almost a decade as academic researcher in Montpellier, France, where he founded his first start-up company, which was taken over by a European Group in 2015. Prior to cofounding and being the CEO of Perseo Pharma, Yves was the CEO and cofounder of INOFEA in Basel.

Dr. Emilie Laprévotte
CDO

Emilie Laprévotte has a PhD in biology, with a specialization in oncology, from Paul Sabatier University (Toulouse, France). During her PhD, in collaboration with Roche Glycart AG, she developed, a new combination therapy using an antibody with a human cytokine for the treatment of hematological malignancies. She subsequently joined OREGA Biotech (Montpellier, France) as project manager, where she established the preclinical proof of concept of antibodies targeting the tumor in solid cancers. In 2017, she joined INOFEA, where she established the early proof of concept of enzzen®-therapeutic enzymes. Emilie is now Chief Development Officer at Perseo Pharma.

Dr. Manon Briand,
Lab Head Medicinal Chemistry – CMC

Manon Briand obtained her PhD from the University of Basel with highest honors in 2021. During her PhD, she worked in tight collab-oration with INOFEA and NBE Therapeutics on the enzzen® technology platform. She developed, among others, new methodologies for the simultaneous site-selective immobilization and protection of enzymes and designed a novel system enabling efficient biocon-jugation on biomolecules (i.e. monoclonal antibodies) and production of antibody-drug conjugates. After the obtention of her PhD di-ploma, she joined Perseo Pharma. With a strong background in Medicinal Chemistry, she now heads our Med Chem Lab and oversees our CMC development.

Prof. Dr. Patrick Shahgaldian
CSO

With a PhD in chemistry from Université Claude Bernard in Lyon, Patrick is a full Professor at the University of Applied Sciences (FHNW) near Basel, where he leads the Molecular Nanotechnology group. He is the main inventor of the enzzen® platform technology and a co-founder of both INOFEA and Perseo pharma. Patrick is the author of more than 90 peer-reviewed publications and of a dozen of patents. His research is well funded through participation in EU- and Swiss-funded projects (H2020, Innosuisse, SNF, etc.). Patrick acts as Chief Scientific Officer for Perseo Pharma.

The Board of Directors

Dr. Werner M. Enz
Chairman

Dr. Enz has held various senior executive positions with Roche in Basel, Canada and Germany, including running Roches largest business unit in oncology, immunology and transplant medicine. After a merger project with Rhône Poulenc Rorer (today Sanofi) in Sweden, he worked for Abbott as Commercial Director Europe in the USA and Divisional Head Hospital business in Switzerland.
Dr. Enz also worked for a number of innovative startups and mid-sized B2B technology companies in life science, leading late stage clinical and business development as well as commercial operations, including as country manager and CEO.
He holds a Doctorate in Medicine from the University of Bern, Switzerland, and an MBA from Edinburgh Business School, Scotland, UK.

Dr. Martin Riediker

Dr. Riediker received his education in Chemistry at the ETHZ and at Princeton University (USA) and in Business und General Management Education at Harvard University (USA). Dr. Riediker has over 30 years of experience in the chemical industry. He has been active as Board member of a number of start-ups and SMEs: Plaxica (Bio-based Chemicals), Polymetrix (PET), Micromacinazione (Pharma), INOFEA (Biocatalysis). Dr. Riediker is a Member of the Commission for Education and Research of economiesuisse, of the SCCER Steering Committee, and is the President of the Steering Committee of the National Research Program 66: Resource Wood as well as the President of Engineering Sciences of Innosuisse.

Prof. Dr. Patrick Shahgaldian

PhD in chemistry from Université Claude Bernard in Lyon, Patrick is now full Professor at the University of Applied Sciences (FHNW) near Basel, where he leads the Molecular Nanotechnology group. He is the main inventor of the enzzen® platform technology and a co-founder of both INOFEA and Perseo pharma. Patrick is the author of more than 90 peer-reviewed publications and of a dozen of patents. His research is well funded through participation in EU- and Swiss-funded projects (H2020, Innosuisse, SNF, etc.). Patrick acts as Chief Scientific Officer for the company.

Stéphane Rousset

Stéphane Rousset
Mr. Rousset is a Business Angel, mentor, advisor, and Board member. He focuses on Swiss technology startups. His corporate career was in the Information and Communications Technology industry. He was a general manager with focus on go-to-market and sales. He held C-level positions at Fujitsu and Oracle, after various leadership positions at Digital Equipment, AT&T, and Global One. He is an alumnus of EPFL, the University of California at Berkeley, and INSEAD.